Validated LC-MS/MS Method for the Determination of Mirodenafil in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of the Free Base and Hydrochloride Salt Forms of Mirodenafil

Abstract

In this study, the pharmacokinetics of 2 forms of mirodenafil, namely the base form and the hydrochloride salt form, were investigated in rats. The 2 forms were orally administered to rats and the plasma concentrations of mirodenafil were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mirodenafil base and hydrochloride salt forms showed similar pharmacokinetic profiles in terms of their maximum plasma concentration (C_max) and area under the concentration-time curve (AUC). The time to peak concentration (T_max) of the base form was slightly greater than that of the salt form, but this difference was not statistically significant. These results suggest that the mirodenafil base and hydrochloride forms are pharmacokinetically equivalent in rats, and thus the base form could be used in various mirodenafil formulations as a substitute for the existing mirodenafil hydrochloride form.

Key words

mirodenafil - comparative pharmacokinetics - rats - LC-MS/MS

*

^*  Tae Kon Kim and Hye Hyun Yoo contributed equally to this work.

• References

• 1 Lee J, Yoo HH, Rhim KJ et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom 2007; 21 (07) 1139-1149
• 2 Yoo HH, Kim NS, Im GJ et al. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta Pharmacol Sin Aug 2007; 28 (08) 1247-1253
• 3 Lee SK, Kim Y, Kim TK et al. Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. J Pharm Biomed Anal Feb 2009; 49 (02) 513-518
• 4 Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008; 68 (02) 231-250
• 5 Engel GL, Farid NA, Faul MM et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000; 198 (02) 239-247
• 6 Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009; 139: 94-107
• 7 Goel H, Rai P, Rana V et al. Orally disintegrating systems: innovations in formulation and technology. Recent Patents on Drug Delivery and Formulation 2008; 2 (03) 258-274
• 8 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf